# Genewell

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/genewell

- Industry: Biotechnology
- Headquarters: Shenzhen, China
- Website: www.gene-well.com
- Latest round: Series B (Aug 12, 2026)
- Investors on record: 5

## About

Based in Guangdong, China, and founded in 2018 by Jinghua Li, Genewell Biotechnology Co., Ltd., trading as Genewell, operates as a molecular diagnostic standards developer that provides in vitro molecular diagnostic tests and related products. Genewell has about 100 employees and many of the core team members come from Cambridge University, Fudan University and the Chinese Academy of Sciences. 
In August 2026, Genewell raised a Series B+ funding led by Tao Capital, with participation from Green Pine Capital Partners.

The company's products divided into tumor, pathogenic microorganism and customized products. Tumor includes pan - tumor 800 gDNA, lung cancer and colorectal cancer gDNA, ctDNA and FFPE. And pan - tumor covers more than 330 genes and more than 720 mutations. Customized products include HRR QC, viral nucleic acid QC, macro genome sequencing QC and HPV nucleic acid detection QC. The company also provides customized service - gene editing service.

The company's revenue is generated by providing gene testing services.

The Series B+ round of financing will further focus on improving the company's product portfolio, expanding into the clinical market, enhancing its large-scale delivery capabilities, and developing its international business.

## Funding rounds

- Series B, Aug 12, 2026 — Green Pine Capital Partners, Tao Capital
- Series C, Mar 4, 2026 — Tao Capital
- Series B, Oct 24, 2022 — Miracle Light Venture Capital, Wedge Investment, Longping Biotech

## Investors

- Miracle Light Venture Capital (https://capitalatlas.ai/funds/miracle-light-venture-capital) — Series B
- Wedge Investment — Series B
- Longping Biotech — Series B
- Tao Capital (https://capitalatlas.ai/funds/tao-capital) — Series C, Series B
- Green Pine Capital Partners (https://capitalatlas.ai/funds/green-pine-capital-partners) — Series B